Is Vacationing
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Just went through CVBT news, here was the reason why it popped from 1.20s to almost $2 the the day.
Reader's Digest Article Calls CVBT's Protein Treatment a 'Gleam of Hope' for Patients with Severe Coronary Heart Disease
CardioVascular BioTherapeutics, Inc. (OTCBB: CVBT) is pleased to announce that its breakthrough angiogenesis therapy has been featured in the February 2008 issue of “Reader’s Digest.” The article, titled, “Heart Hope” by Lisa Collier Cool, refers to CVBT’s therapy as a “new lease on life” for patients suffering from severe coronary heart disease who do not have any other viable treatment options. Patients such as those featured in the Reader’s Digest article could benefit from this innovative treatment where conventional methods have failed them. Angiogenesis refers to the growth of new blood vessels that may help those suffering from coronary heart disease by increasing blood flow to the affected tissue.
Jim Blevins and Gail Keller, both patients of Dr. Lynne Wagoner, were what some refer to as “no option patients” for whom all of the “conventional treatments had been exhausted.” Dr. Wagoner was the principal investigator in CVBT’s completed Phase I Coronary Heart Disease trial. She learned of CVBT’s new procedure in which its drug, containing the active protein fibroblast growth factor-1 (FGF-1), was injected into the heart thereby stimulating angiogenesis. In the article, Thomas J. Stegmann, MD, co-founder, co-president, and chief medical officer of CVBT explains, “the protein is like a seed that causes new vessels to sprout, creating a network of capillaries and small arteries.” Once admitted into the trial, Gail Keller felt “thrilled and elated to finally have hope.” In the article Gail continued, “I had nothing to lose, because the quality of my life was so bad.” Before participating in the trial, Jim Blevins had been “dreading the future thinking that I’d go into heart failure again and only have a few years left.” Jim continued, “within a few months of being treated, my energy was up at least 50 percent.” Both Jim and Gail had successful outcomes from the Phase I trial and have been able to get back to activities that were once thought to be lost to them forever such as golf, biking and gardening.
Improving the quality of life for these patients through improvement of myocardial blood supply is CVBT’s main objective. “We are pleased about being highlighted by ‘Reader’s Digest’ for our intensive work in the field of angiogenesis therapy,” said Dr. Stegmann. “Our goal is to provide a viable treatment that gives heart disease patients hope and can return them to the quality of life they once enjoyed.”
The Phase II study will utilize an injection catheter to deliver the drug to ischemic regions in the heart wall without surgery. It is less invasive than the surgical delivery of the drug used in the Phase I trial. The Phase II trial will also permit the comparison of the benefits of CVBT’s drug candidate with the requirement of a placebo control group. CardioVascular BioTherapeutics is expected to begin its Phase II clinical trial of its drug candidate CVBT-141H for the treatment of severe coronary heart disease in the coming months. For more details please visit www.cvbt.com.
About CardioVascular BioTherapeutics
CVBT is a biopharmaceutical company developing drug candidates with FGF-1 as its active pharmaceutical ingredient (API) for diseases characterized by inadequate blood flow to a tissue or organ. The company has FDA-authorization for a Phase II trial to treat severe Coronary Heart Disease (CVBT-141H) and a Phase I trial to treat Peripheral Arterial Disease (CVBT-141C). A Phase Ib or Phase II trial to treat dermal wound healing in diabetics (CVBT-141B) is planned to begin in 2008.
CVBT 1.31 x 1.32......
This is what's showen on my level 2 on SOL:
CVBT 1.30 x 1.31
Gentelmen, start your engine please.
ETFC is over $4... CEO sent another message to all clients to buy ETFC, I bought some again at Eturd, lol.
OUR CUSTOMERS
We've never been happier to see a year come to an end or more excited to start the next. With the release today of our 2007 earnings report, we can now focus on 2008 and the progress ahead.
Why the optimism? There are several reasons:
We Have a Strong and Growing Retail Business Focused on the Customer
As detailed in our 2007 results, despite the challenges we faced in the fourth quarter, we have a strong and thriving retail business. The number of gross new US retail brokerage accounts opened during the year increased by 39% vs. the prior year and the number of gross new bank accounts increased by 80%. We continued to attract impressive numbers of new customers, and on average over 3,000 new accounts opened a day in every quarter in 20071 and the vast majority of our customers stuck with us. This is a testament to the continued strength of our brand.
We Continue to Innovate
Innovation and cutting-edge technology have always been at the heart of our culture. In 2008, we expect to introduce several exciting new products and services for our customers. You can look forward to E*TRADE Mobile Pro, a fully integrated trading and banking platform for wireless devices; a new suite of online retirement planning tools; upgrades to the E*TRADE Global Trading, Power E*TRADE Pro and E*TRADE MarketTrader platforms; and enhanced relationship management and customer service. You'll continue to enjoy free Quick Transfer, and checking and savings account yields that are among the highest in the nation. In short, in 2008, you can expect an even better experience at E*TRADE.
We Continue to Strengthen the Balance Sheet
In November, we announced a $2.5 billion cash infusion that strengthened the Company's capital position and removed $3 billion of asset-backed securities from the balance sheet. E*TRADE remains well-capitalized by regulatory standards, and we plan to end the year with nearly $1 billion in excess Bank capital. Further, we've exited our wholesale mortgage business as well as our Institutional Trading operations in the US and internationally, ensuring a strict focus on our core retail business.
Your Assets Are Well Protected
We remain steadfast in our commitment to safeguard your assets at E*TRADE (click here for details):
100% Customer Securities Protection. At E*TRADE Securities, all fully-paid customer securities, including stocks and bonds, are 100% owned by the customer.
E*TRADE Securities is a member of SIPC which protects securities customers of its members up to $500,000 (including $100,000 for claims for cash).
E*TRADE Bank accounts are FDIC insured to at least $100,000.
E*TRADE Clearing has purchased additional protection of up to $150 million per brokerage account through its London insurers (aggregate, all customers, $600 million).
We understand that you want to make sure your assets are protected, that you receive the best possible customer service, and that you can depend on our platform. In a week like this, with significant market volatility and industry-wide high trading volumes, it's worth noting that our systems and people performed flawlessly — despite a record number of concurrent users logged onto our website. Our ability to handle these volumes is one of the reasons E*TRADE Securities has been repeatedly recognized by Keynote as the #1 Online Brokerage for Speed and Reliability.
With 2007 behind us, we are inspired to work harder than ever to demonstrate the strength and value of E*TRADE. That means reinvigorating the things that make E*TRADE unique — challenging the industry status quo with innovation, cutting-edge tools, technology, and value.
We hope you share our optimism for 2008.
Jarrett Lilien
Acting Chief Executive Officer, E*TRADE FINANCIAL
CVBT 1.26 x 1.28, it is warming up.
SOL shows trading down 15 from 27.99 close? SOL missed the the solar momo.
BFTH is going crazy.
Scottrade is up......
I don't know anything about the stock, just pop up on my scanner, like the chart, that's all.
Today PUDC has been acting weak after filled the gap to 0.74. Still have some shares, but don't get greedy, watch and see. Might retest 0.74 again, break it, will ride it, if not, sell the rest.
CVBT 1.23 x 1.25
Chart:
CVBT 1.23 x 1.25
Chart:
AVNR and UXG nice charts. Will put AVNR in my competition entry for tomorrow.
Cannot believe this Chinese student won the top prize and $13500 with a mere 9% gain for the past quarter at Yalicoo. Many of us can beat him
...........
Diexia Wang, Student
Prize Won: $13550 Competition: NASDAQ Largest 750 Companies
PUDC has a very nice finish, might look for one or two more nice candles like it did in early Dec:
Thanks T. Might add SNEN to that group too.
Hope you are having a great vacation!
PUDC $0.70 very nice finish:
PUDC $0.70 very nice finish:
Why not use quotetracker? it is free
NYNY had a pretty good day..
PUDC - what a nice finish at $0.70!
Okay, all traders, think you're good? Then go to the free virtual competition and win daily/weekly cash prizes
See my signature...
Yep, VMW - what a tank....
T, you sure will have a great time over there, enjoy and forget about the stocks, lol.
We went to Playa Del Carmen, Cozumel, Calica, and Tulum through excursions on a cruise trip last year, it is one of the best areas to visit.
Have a great trip!
Thanks! I feel PUDC could go to 0.70-0.80 early next week.
PUDC HOD $0.62!
I couldn't agree more with you on this. Definitely looking very good on PTSC. All the hurdles are gone, the only thing left is to reap the gains and collect $$ from these chip makers.
PUDC 0.59 - PUDC is charging up for the last 30 minutes.
Also CJGH shall go next week, put it on your radar!
A pullback on stocks like GOOG after went up $80 points in two days is normal and doesn't take the greatest contrarian to figure it out.
Here is how PDUC performed right after a Doji, hold on for three days and see.
PUDC chart, possible just starting:
PUDC is 1st day, looking for more to come next week.
PUDC 0.60s
PUDC 60 x 0.62.
PUDC 0.58 x 0.60, wee!
PUDC 0.57 x 0.58, there is a gap to fill at 0.70s.
PUDC 0.55 x 0.56!
PTSC monthly chart:
CJGH is finally starting 0.82.